Seroprevalence of HHV8 in Mozambique in relation with HIV/AIDS. Clinical evidence of Kaposi Sarcoma in a HIV+ cohort. Correlation with immune and viral state and Sarcoma regression in patients under HAART and treated or not treated with cytostatics by Ceffa, Susanna
 1
University of Pisa 
 
 
 
 
 
 
BIOS 
Research Doctorate School in BIOmolecular Sciences 
 
 
Experimental and Molecular Oncology 
 
 
Ph.D. thesis: “Seroprevalence of HHV8 in Mozambique in relation with HIV/AIDS. Clinical 
evidence of Kaposi Sarcoma in a HIV+ cohort. Correlation with immune and viral state and 
Sarcoma regression in patients under HAART and treated or not treated with cytostatics.” 
 
Teacher: Prof. Generoso Bevilacqua 
 
 
Student: dr. Susanna Ceffa 
 
 
 
 
 
 
 
Academic Year 2005/2006 
 
 2
 
INDEX. 
 
Introduction:  
A) The Kaposi Sarcoma    p. 4 
Symptoms.      p. 4 
    Aetiology: the Human herpes virus 8   p. 5 
 Transmission     p. 6 
Sarcoma development: possible co factors. p. 7 
HHV8 and HIV      p. 8 
    HHV8 and KS in Sub Saharan Africa  p.11 
    KS in the HAART age    p.12 
    KS treatment     p.14 
 
B) The DREAM Program    p. 17 
The HIV/AIDS pandemic    p. 17 
The antiretroviral therapy    p.17 
A public health intervention   p.19 
Day hospital and home assistance  p.20 
The laboratory     p.21 
Computerization.     p.21 
DREAM laboratory’s  implementation  p.21 
 Cost-reduced analytical methods   p.22 
 
Materials and Methods 
Sample and sampling     p.24 
Testing      p.25 
Antibody detection for HIV     p.26 
Quantification of HIV1 viral RNA.   p.27 
Direct research of HHV8 by qualitative PCR  p.27 
HHV8 antibody detection    p.28 
Immunophenotyping for the determination of 
 CD4+ and CD8+ T lymphocytes   p.28 
 Statistical analysis     p.30 
 
 3
Results           p.31 
 
 Discussion           p.48 
HHV8 prevalence in Mozambique   p.50 
Kaposi Sarcoma in HIV+ patients under ARV  
and treated or not treated with chemotherapy  p.51 
 Machava centre: Patients with  Kaposi Sarcoma p.53 
 
Conclusions           p.56 
 
Acknowledgments          p.59 
 
References           p.60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
INTRODUCTION 
 
Kaposi ‘s Sarcoma (KS) was first described in 1872 by the Hungarian dermatologist Moritz 
Kaposi.  
There are four different forms of KS: 
Classic KS causes multiple skin lesions on the lower limbs. It is mainly seen in elderly men 
in Mediterranean or Eastern European regions. 
Endemic (African) KS is found in children and young men in equatorial Africa. It is more 
virulent than the classic form. 
Acquired (Posttransplant) KS occurs in people treated with immunosuppressive drugs, 
especially those who have received organs transplants. It goes away when the drugs are 
stopped. 
Epidemic (AIDS related) KS is the form associated with HIV infection. It tends to follow a 
more variable but potentially more aggressive course than other forms of KS. 
KS is an angioproliferative illness with multifactor origin and several types differing in their 
clinical and epidemiological patterns. It generally arises like an inflammatory hyperplasia, 
and the angiogenesis process  plays a primary role in the deve lopment of the disease. It 
evolves into disseminated nodular lesions which are very much alike a  true sarcoma.  
KS most commonly presents as skin lesions which often appear when the immune system 
is still relatively intact. As long as it is confined to the skin, KS is not fatal and it is unlikely 
to be serious. 
While it is most commonly found on the skin, KS can occur anywhere in the body. 
A major advance in our comprehension of KS epidemiology came from studying the 
distribution of 13.616 cases among 90.990 persons  with AIDS reported to the Centres for 
Disease Control, Atlanta, until March 31, 1989. Detection of KS in 21% of males who 
acquired HIV1 through homosexual or bisexual contacts in comparison with <7% in all 
other HIV transmission group such as heterosexuals of Caribbean, African and other 
origin, intravenous drug users, transfusion recipients and persons with haemophilia 
suggested that AIDS KS might be a sexually transmitted infection (11)  
 
Symptoms. 
When KS lesions first appear on the skin, they are often flat patches with a pink or blood-
bruise colour in white people. In black people as hyper pigmented black patches. They 
develop into nodules: hard, raised, round or oval lumps. Their colours is violet, bluish or 
reddish in light-skinned people. When the nodules are present, they often appear in 
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roughly symmetrical patters on each side of the body and may follow the skin fold lines of 
the body. In some cases, the nodules can ulcerate, bleed and become infected. 
Lesions can appear also in lymph nodes, lungs or intestine. In intestine, KS is usually 
harmless but can sometimes cause a blockage, resulting in nausea, vomiting, abdominal 
pain and occasionally bleeding. 
In the lymph nodes, blocked fluid drainage may cause swelling, especially in the feet, 
lower legs or genitals. Occasionally swelling can occurs around the eyes. 
Pulmonary KS is the most serious form, and can be fatal. It can lead to recurrent chest 
infections or accumulation of fluid on the lung (pleural effusion). There may be blood in 
split, cough and breathlessness. 
KS lesions sometimes occur in addition to a condition to a condition called Multicentric 
Castleman’s Disease (MCD). This is a disorder of resulting from over-activity of lymph 
tissue. MCD is characterised by swollen lymph nodes, fever, fatigue, weight loss, night 
sweats, blood disorders and sometimes liver and spleen irregularities.  
 
Aetiology: the Human herpes virus 8 
The manifestation of the disease is strongly related with the infection by HHV8 Human 
Herpesvirus (16),  and the seroconversion to HHV8 preceded the onset of KS in every 
case. (97). This is an herpes virus, first named Kaposi’s sarcoma associated herpesvirus 
(KSHV). 
In 1994 the group of Yuan Chang (30), using the method for searching DNA sequences 
differently expressed in KS and normal tissues, put into evidence, in the Kaposi sarcoma 
lesions, a herpesvirus-like DNA sequence, named KSHV or HHV-8. In March 1996 
researchers in San Francisco successfully grew the virus in culture.  
The new sequences showed relevant levels of homologies with oncogenic gamma-
herpesvirus sequences (Herpesvirus saimiri and Epstein-Barr virus). Using RT-PCR, the 
HHV-8 sequences were found in all epidemiological forms of Kaposi: 
HHV-8 was also found in a rare B lymphoma (BLCB) and in the Castleman syndrome, a 
rare disease with poor prognosis. 
KS is the result of various stimuli promoting the micro vascular inflammation. 
Sequence analysis placed HHV8 (named also Kaposi Sarcoma Herpes Virus, KSHV) in 
the gamma2 (Rhadinovirus) lineage of the gammaherpesvirinae along with Herpesvirus 
Saimiri (HVS). The closest human relative is the gamma1 (Lymphoxryptovirus) 
herpesvirus Epstein Barr Virus (EBV). This finding is intriguing for the relationship that 
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gammaherpesviruses have with lymphoproliferative disorders and cancers: HVS can 
induce malignant lymphomas in owl monkeys  and EBV infection is linked to a fatal B cell 
proliferation in young males with lymphoproliferative disease, posttranplant lymphomas, 
immunoblastic lymphomas in AIDS patients, Burkitt’s lymphoma, Nasopharyngeal 
Carcinoma and Hodgkin’s Disease. 
The genome of HHV8 has a 140,5 kb-long unique region (LUR) which is flanked by 
multiple 801 bp terminal repeat sequences. Within the LUR, 81 potential Open Reading 
Frames (ORFs) with more than 100 amino acids have been identified, and several 
additional spliced genes have since been added to this list. The numbering of HHV8 ORFs 
is based on positional homologies with HVS due to substantial co-linearity between these 
genomes whereas ORFs without positional homologues are numbered consecutively with 
a K prefix. The presence in the viral genome of open reading frames  with significant 
homology to mammalian genes involved in cellular growth control, suggests that 
“molecular mimicry of cell cycle regulatory and signalling proteins is a prominent feature of 
this virus” (123) 
Comparison of protein sequences predicted from the genomes of Varicella Zooster virus 
(VZV) and EBV suggests a common mammalian herpes viral ancestor. (35) 
Analysis of genome suggests that 42 genes are common to a set of genes that the 
mammalian herpes viral ancestor may have possessed.  
The most variable region to date in the HHV8 genome appears to be OFRK1. 
Phylogenetic analyses using ORFK1 sequences obtained from different geographic 
regions, including Classic and AIDS KS, enabled the definition of 4 major subtypes, A-D. 
The subtype B is predominated in Africa, while subtypes A and C were found more 
frequently in Europe. No correlation was noted between subtype and more aggressive 
HHV8 related disease, or geographic regions.(33) 
 
Transmission 
HHV8 is spread sexually, through mother to child contact, and via organ transplant. A 
group of studies suggests that the relatively high levels of HHV8 in saliva may also 
contribute to HHV8 transmission. (115, 24) 
Sexual transmission 
Formal evidence has been acquired using seroepidemiological results from several cross-
sectional and prospective cohort studies on homosexual men. Sexual transmission and 
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particularly homosexual transmission were reported from the Sydney HIV cohort (62) the 
San Francisco Young Men Study (14) and from an important cohort in London (130). 
Childhood transimssion 
Transmission  before puberty appears to be rare in the United States (15) but does occur 
in countries where HHV8 is more widespread. Evidence for intrafamilial clustering has 
been seen in Italy (5) and it is measured also in Uganda ((93) Cameroon (56) Egypt (4)  
South Africa. Prevalence of HHV8 is high in this last setting and transmission appears to 
be occurring  in childhood as well as among adults, increased in later adulthood (< 18 
months 37.5%, 19-120 months 38.5%, 15-34 years 32.1%, 35-69 years 62.8%). (143).  
Most of the paediatric cases were aged 6-10 years. A significant increase in the 
occurrence of total childhood cancers was found. This is mostly due to a highly significant 
increase in the incidence of paediatric Kaposi's sarcoma (p = 0.000016), which is causally 
related to HIV infection, and a significant increase in the incidence of retinoblastoma (p = 
0.02), which has an unknown relation to HIV infection (113).  
 Infection in children less than 10, are probably the results of mother to child transmission, 
although whether this occured pre- peri- and post-partum is not yet known (19). A sequent 
study showed that the probability of mother to child transmission increased with increasing 
maternal antibody titer (123) In children less than 2 years, HHV8 infection is however rare, 
even in endemic countries, arguing against transmission through breast milk (56, 60, 86, 
93.) 
Parenteral transmission 
The presence of HHV8 antibodies prior to transplantation in transplanted patients suggest 
that Posttransplant KS is mainly due to reactivation of HHV8 (112 50) KS remission seems 
to coincide with reduction or cessation of immunosuppression (102) 1998) Evidence is 
mixed on transmissibility of HHV8 by blood transfusion.(14), (91) (94) reported an 
association with blood transfusion in Ugandian children. 
 
Sarcoma development: Possible co factors.  
It is evident that the incidence of HHV-8 infection is far higher than the prevalence of KS, 
suggesting that viral infection per se is not sufficient for the development of aggressive 
phenotype and that one or more additional cofactors are required. Some studies found an 
association between high anti HHV8 antibody titre and an old age, but other associations 
that may be factors in the development of high anti HHV8 titers include exposure to 
poverty or a low socioeconomic status environment and consumption of traditional maize 
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beer. (144) One hypothesis suggests that KS develops because the immune system is 
over-activated, with elevated cytochine levels stimulating the growth of early KS cells, 
which can eventually become cancerous. Once these cells have arisen in one part of the 
body they may spread in the bloodstream until they lodge in other tissues to cause 
additional lesions. Several cofactors have been supposed for the  development  of the 
Kaposi sarcoma, for example oncostatine M (98). Oncostatin M is a growth factor that is 
secreted by activated T cells that stimulates angiogenesis. An other proposed factor was 
the human papilloma virus, (HPV) (69). HPV 16 related DNA sequences in Kaposi’s 
Sarcoma. Lancet 339:515-518, 1992) associated with cervical and anal cancer. 
Environmental cofactors are proposed (142) and iron exposure (126). Ttransmission of 
HHV8 infection it seems facilitated by contact with blood sucking arthropods (31). 
 
HHV8 and HIV  
Also the presence of HIV itself play a role in KS. Infections such as HIV that activate T 
cells, may lead to increase in levels of Oncostatin M. Studies have shown that the HIV tat 
gene seems cause the development of KS-like lesions in mice, and the Tat protein 
produced by this gene stimulates the growth of human cells in test tubes and the 
progression of KS appears to be due to the deregulated expression of oncogenes and 
oncosuppressor genes, to the long-lasting expression of the HHV8 latency genes 
promoted by the proliferative and angiogenic effects of the HIV-1 Tat protein (23, 49). 
 In a study (29) plasmas of 18 Tanzanians with sarcoma were analysed. Of them, 14 were 
14 HIV+. Among these patients, the HHV8 viral load shows a median of 2075 copies/ml; in 
the negative group it is 450 copies/ml. Despite the exiguity of the sample, this datum 
seems to suggest a cross-signalling pathways between the tat protein and HHV8 DNA in 
the pathogenesis of KS. 
 
HHV8 bears a gene (K1) encoding a transmembrane protein with an immunoreceptor 
tyrosine-based activation motif. This motif is present in receptors that mediate 
inflammation, K1 may activate cells in which it is expressed, as well as other cells in a 
paracrine manner. K1 cooperates in signaling with HIV -1 Tat, suggesting that both of the 
proteins from these viruses converge to reach an enhanced level of inflammation that may 
underlie progressive KS.(124) The level of nucleotide sequence of K1 gene was studied in 
a Zimbabwean group of 500 subjects. Data provide evidence of the relationship between 
HHV8 lytic replication and untreated HIV1 infection (21). 
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Morini (103) had proved that HIV tat can activate sarcoma cells derived from sporadic or 
iatrogenic lesions, suggesting that in patients with AIDS tat can cooperate with VEGF, thus 
contributing to the aggressiveness of the KS/AIDS lesions, and levels of VEGF-A are 
higher in HIV+ patients, with or without KS, compared with individuals without HIV infection 
(7). However, the serum concentration of VEGF does not seem to be useful for monitoring 
the disease progression, since it is not directly linked with the HIV1 or HHV8 infection, or 
with conditions associated with Kaposi sarcoma in AIDS. (120).  
In the case of coinfection HHV8/HIV1 it is interesting to notice the correlation between the  
viral loads of HHV8 and HIV1. In a study (134) on 54 consecutive p lasma samples from 
HIV1+ patients with Kaposi, an association between the two viremias was found, even if 
both positive and negative trends have been observed. An association with the value of 
CD4+ lymphocytes has also been found, while high HHV8 viral loads correlate also with 
HHV8 antibody titres measured with immunofluorescence. Other data, instead, (12)  
suggest that the HHV8 viral load in patients with KS is relatively low, and does not differ in 
HIV1- or HIV+ patients. 
 
Also an higher HHV8 antibody titre is associated with the risk to develop KS (121) It is 
apparent that, as the HIV epidemic advances in regions of the world with endemic KS, the 
clinical presentation and natural history of the endemic KS are blending with those of the 
epidemic or AIDS-associated disease, leading to a reduction in the mean age of the cases 
and a nearly identical incidence in men and women. In regions of the world where patients 
have ready access to such chemotherapy, the impact of treatment with highly active 
antiretroviral drugs on the incidence and natural history of KS has been dramatic (105)  
Some studies showed a high HHV8 seroprevalence in HIV1+ groups, and evidenced the 
association between HHV8 antibody levels and immunologic state, or antibody titre and 
risk of  developing Ks (76). 
In effect human immunodeficiency virus and KS herpesvirus/human herpesvirus-8 
(KSHV/HHV8) co infection, leads to the development of an angiogenic-inflammatory state 
that is critical in the pathogenesis of KS. KS is driven by KSHV/HHV8-specific pathways, 
which include viral G protein-coupled receptor (vGPCR), viral interleukin-6 (vIL-6), and 
viral chemokine homologues. In addition, cellular growth/angiogenic pathways, such as 
vascular endothelial growth factor (VEGF), insulin-like growth factor, platelet-derived 
growth factor (PDGF), angiopoietin and matrix metalloproteinases (MMPs) are "pirated" by 
KSHV/HHV8 (39, 40) 
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Therefore in Western countries, the KS diffusion is epidemiological related with HIV-1 
infection, where historically KS is diagnostic of AIDS. During the initial phase of the AIDS 
epidemic, KS was only observed in men who had homosexual relations. Some studies 
show that one third of patients with HIV1 HHV8 co infection can develop sarcoma. KS 
used to be the most commonly diagnosed HIV related malignancy. With the development 
of better treatments of KS and the use of antiretroviral therapy, the incidence of KS 
declined significantly at the end of the 1990s in Western Countries and it is rarely a cause 
of death. Nerveless, KS is associated  with an elevated risk of death and there is some 
evidence that it can accelerate HIV disease.  
The reason why some people infected with both HIV and HHV8 develop KS while others 
do not, appears to be linked to HHV8 rather than CD4 cell count. A study found that the 
presence of HHV8 genetic material in both blood cells and saliva was associated with KS, 
while people with HHV8 only in saliva were much less likely to have KS lesions (22) 
Many studies focused the relationship between the two viruses in Western Countries (1, 
34, 44, 71, 116) like in the EuroSIDA study, or in the study of Rezza et al. (121) in Italy to 
evaluate temporal trends of Kaposi's sarcoma (KS) and of the KS-related human 
herpesvirus (HHV-8) among homosexual men who seroconverted for HIV between 1984 
and 1997 ( 122). 
 
The introduction of highly active antiretroviral therapy (HAART) has radically changed the 
clinical course of human immunodeficiency virus (HIV) infection. The EuroSIDA Study 
study assessed the change in the incidence of Kaposi sarcoma (KS) among European 
patients with HIV since the introduction of HAART and to identify the factors associated 
with the development of KS among patients receiving HAART. The current incidence of KS 
among patients with HIV is less than 10% of the incidence reported in 1994 and most 
individuals who developed KS while receiving HAART began treatment with low CD4 cell 
counts and developed KS within 6 months of the initiation of HAART (101)   
Atkinson (8) identified AIDS related KS cases in linked United States, AIDS and cancer 
registries for 164.000 people. KS incidence was highest in gay men, lower for 
heterosexual men and lowest for women (5,7 vs 0,4 per 100 person years). Relative risk 
adjusted for age, race, location and year of AIDS onset for injecting drug use were o,9 
(95% CI 0,8, 0,9) for gay men, 1,1 (95% CI 0,7, 1,6) for hetesexual men and 1,3 (95% CI 
0,9, 1,8) for women.  
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Analysing the epidemiology of KS in Scotland, Brewster (20)  noted that the AIDS 
associated KS was associated with an increased morbidity and shorter survival, compared 
with the traditional, non AIDS KS seen in older men.  
Gao reported that in the Multicenter AIDS Cohort Study the median time from 
seroconversion to HHV8 and development of KS was 33 months (range 6-75 months) (53)  
Studies of antibody kinetics for IgG against HHV8 put into evidence that more than half the 
patients with KS/AIDS had seroconversion before developing sarcoma, but it does not 
seem that the risk of developing the tumour is strictly associated with the duration of the 
infection.  
The immune effects of HHV8 in healthy adults consist of the chronic inhibition of the type 
1-cytotoxic response of T cells, not depending from the HIV infection (37). 
 
HHV8 and KS in Sub Saharan Africa 
Data on HV negative patients HHV8 prevalence and KS incidence in Africa are scarce. A 
little more works are founded about HIV epidemic and KS disease.  
In Sub-Saharan Africa the HIV epidemic has a high prevalence, but in these areas the KS 
can be found also in HIV negative patients, and according to some studies, the HHV8 virus 
diffusion is endemic. A study brought on in Malawi (37) in a cohort made of 272 patients 
and 24 healthy individuals, Seroprevalence is between  67% and 54% respectively; it 
grows with age, but it is not linked with HIV positivity, nor with the percentage of CD4 
lymphocytes, nor the diagnosis of Kaposi (10 cases in total). Women show lower titres 
than men. In Zambia a study determined virus prevalence estimates and the risk factors 
associated with HHV-8 infection. Cross-sectional, enrolment visit data were analyzed from 
a prospective cohort study of perinatal transmission of HHV-8. Among 3,160 antenatal 
women serologically screened for HHV-8 40.2% were seropositive. (79) 
Nevertheless, the Kaposi sarcoma associated with AIDS (AKS) is particularly aggressive, 
and is one of the main neoplasias in the Africans areas affected by both viruses. 
Kaposi is endemic in South Africa well before AIDS epidemic. It is now growing, (127) and 
it seems that the risk of developing sarcoma is associated with antibody levels, but at a 
given titre the risk is higher for HIV+ subjects compared with HIV- subjects. In hospitalised 
coloured patients seroprevalence is about 30% adjusted by age and sex. It grows with age 
and it is similar in men and women. Seroprevalence lowers with levels of education, and it 
is lower in the whites than in the blacks. (129) In an other study (144)  in a sample of 2191 
HIV-1 negative patients black in-patients in Johannesburg and Soweto, South Africa, 
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39.0% were positive for antibodies against HHV-8. Patients with high anti-HHV-8 antibody 
titers are characterized by older age. In Uganda, where the KS in a common cancer, the 
seroprevalence is 47% in a blood donor group. (66). 
In Zambia (63) prevalence results to be 48.4% in pregnant women, with a prevalence of 
51.1% among HIV-positive women and 47.3% among HIV-negative women. 
A study by Phiri (117) in Zambia shows a prevalence of 25% in 36-months-old children, 
while seropositive children or children born to seropositive mothers are more easily 
infected by HHV8. 
In other African coutries, the situation seems slightly different, as shown by a study 
conducted on 407 pregnant women in Senegal, where the prevalence of sarcoma is low 
also in people with HIV. 14.3 % of the studied population resulted positive for HHV8 
antibodies and did not show coinfection with HIV. Prevalence was higher among 
miscarrying women (17.2% vs. 4.9%). Moreover, an association has been revealed 
between mother infection and low weight of children at birth (54).  
Just to mention some data to have an idea, in Japanese healthy adults seroprevalence is 
0.2%. (51) In Northern Europe it is 3 -7%, while it grows in Southern Europe. In Italy and 
Greece it is 35% (119).  
The detection of HHV8 in PBMCs of AIDS –KS patients and HIV infected controls, has 
demonstrated a strong association between HHV8 infection and KS, even in a region of 
high HHV8 seroprevalence as The Gambia (6).  
 
KS in the HAART age 
In Countries with limited resources, in the absence of highly active antiretroviral therapy 
(HAART), KS was treated for palliative reasons with chemotherapy or not treated at all. 
Less than 1% of AIDS patients are receiving HAART in sub Saharian Africa yet, (95) but 
with the increase of the use of HAART also in developing countries the way to treat KS 
could dramatically change. In United States for example before the era of HAART 15% of 
HIV patients presented KS as the primary AIDS defining event.(65). Over the past two 
decades, in several African Countries with high HIV prevalence, the KS incidence have 
seen a 10- 20 fold increase. In Western Countries HAART has caused a sharp decline in 
the incidence of the disease, due to the immune restoration following the antiretroviral 
treatment and there are indications that this coincides with immune control of HHV8. 
In effect, AIDS correlated KS could be considerate   as an Opportunistic Infection (OI). In 
absence of HAART there is no cure for AIDS KS. No local or systemic therapy has proven 
 13
to increase survival. Chemotherapy is often used when patients have important lesions in 
visible area of the body, extensive painful skin lesions and oedema, oral lesions that cause 
obstruction or evidence of a rapid tumour progression. The natural history of the KS is 
changed with HAART. Several studies have shown a response rate up to 90% after two 
years of HAART treatment. ( (46). Bourboulia at al. report that there is an apparent 
restoration after a relatively long (> 24 months) period of treatment, bur they think these 
immune responses could contribute to the decreased incidence of KS during HAART, but 
it is unlikely to be a complete explanation for the often rapid resolution of KS when HAART 
is started (18)  Once patients are responding to therapy (partial or complete response) the 
chemotherapy can be interrupted while immune restoration does the work, even in 
pulmonary KS (87) 
 
Some studies compared different regimens based on non nucleoside reverse transcriptase 
inhibitors or protease inhibitors (118). 
The effectiveness of the antiretroviral therapy seems to be demonstrated, particularly 
using protease inhibitors, to achieve the regression of AIDS-related sarcoma. The clinical 
response correlates with the decrement of plasmatic levels of RNA and the increment of 
CD4+ T-lymphocytes. (26). 
Some authors  analyzed data from a group of HIV positive patients presenting with KS and 
under HAART, demonstrating that there were no differences between patients in remission 
and progression in age, CD4 cell count, and HIV VL at KS diagnosis. In a study of 
Thirlwell, was reported that, among 70 HIV infected patients with KS, 9 had visceral organ 
involvement, CD4 cell count average at 212, and 11 with undetectable viral load. 20 of 
them were o HAART. Of the 50 not on HAART at diagnosis, 35 were treated only with 
HAART and at one year, only 5 of these patients required chemotherapy. Tirelli reported 
that the HAART may be a useful alternative to immune response modifiers (es interferon) 
during the less aggressive stages of KS. In a study of  was reported that HAART was 
associated with an improved survival (p=0,0001) and 81% reduced risk of death. Also in 
the Swiss HIV Cohort Study AIDS defining illnesses including KS declined by about 80%. 
A retrospective study in New York demonstrated the significantly longer survival in HIV 
infected patients with KS treated with HAART. Complete or good KS remission was 
reported in Dupin studies. (45, 83, 135). 
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KS treatment 
There is a range of treatments available for KS. These include local or general 
chemotherapy and pathogenesis-based treatments.  
Local therapy consists in localised radiation therapy (radiotherapy) it can be used to treat 
KS lesions in the mouth or throat, painful skin lesions or lesions that are causing 
blockages in the lymph nodes of the  face, arms and legs. Radiotherapy kills the overactive 
tumour cells with a series of low doses of radiation, leaving the rest of the body untouched. 
Side-effects can include short-term reddening of the skin, hair loss and, in the mouth, 
inflammation of the mucous membranes. The lesions usually leave a scar, like a mile, 
where pigmentation remains in the skin.  
Other approaches to treating skin lesions include removing them surgically or freezing 
them with liquid nitrogen (cryotherapy). 
Interferon alpha has been reported as a helpful treatment. The best results were reported 
when it was used to treat early KS. 
Cytotoxic chemotherapy is the most used treatment in limited resource Countries, but 
could cause different side-effects, of course. Usually it is used a combination of three 
different drugs, doxorubicin, bleomycin and vincristine (ABV). 
In Mozambique, particularly, the protocol provide, based on corporal surface calculation, 
the following drugs: 
Doxorrubicina 50mg, maximum 500 mg/month (monthly treatment cycle).  The first day 
doxorrubicina half dose and the second day half doxorrubicina dose+vincristina + 
bleomicina.  
The Vincristina dose is 1,4mg and maximum 2 mg/month.  
The Bleomicina dose is 10-20 units monthly, diluted in physiologic, maximum 400 units 
monthly 
This combination increase the median survival in patients with aggressive cutaneous or 
visceral KS, as reported in several papers, first in Gill (57).  
In Europe and United States, researchers have developed new, less toxic formulations of 
chemotherapy drugs. Two drugs, liposomal doxorubicin and liposomal daunorubicin are 
now considered to be the standard of care for KS. Other therapies, such as angiogenesis 
inhibitors, are under investigation in clinical trials. (2). 
Nerveless,  ABV seems to be the most reasonable treatment option for AIDS-KS patients 
in resource-limited countries at the moment, comparing the cost-effectiveness of other kind 
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of treatment (pegylated liposomal doxorubicin (PLD) and liposomal daunorubicin (DNX)). 
(139). 
 
Recently, researchers have started to look for drugs that inhibit HHV8. as drugs used to 
treat other herpes virus infections, such as ganciclovir, foscarnet, cidofovir and aciclovir. 
Even if the effects of the cidofovir is controversial,  some authors reported effects used  in 
association with liposomal daunorubicin. (140). 
The choice of  treatment for Kaposi Sarcoma in AIDS patients in Western Countries 
depends on several factors.  
It includes of course an attentive evaluation of disease extension, but also of the 
progression rapidity, symptoms,  and of the objective to join.  
The maximum HIV suppression associated to Oppurtunistic Infection (IO) prophylaxis  and 
treatment are crucial instruments also in Kaposi Sarcoma therapy. 
In patients with spread and proliferati ve muco cutaneous  disease, the systemic therapy 
could just consist in HAART administration. The HAART therapy, as primary therapy, gives 
an objective remission rate of 66-68%, with a complete remission rate of about 35%. The 
needed average time to obtain a complete response is normally between 2 and 4 months 
and the anti neoplastic response is generally correlated with the patient's immunological 
reconstitution (106). The chemotherapy treatment is reserved to patients with quickly 
progressive disease, visceral symptomatic disease, pulmonary localization  and/or 
important oedema. The chemotherapy is indicated also in patients with neoplastic 
progression on HAART treatment.  
 
Several chemotherapy drugs, when used in a single combination, show an activity in 
treating Kaposi Sarcoma in HIV/AIDS patients. They are adriamicine (ADM), the vinca’s 
alkaloids (V) (vinblastine, vincristine, vindesine, vinorelbine), bleomicine (B) and taxole 
(TAX), and allow to obtain some objective responses with a response rate between 30 and 
70 %, while in a large amount the responses consist of partial remissions.  
In Kaposi Sarcoma treatment, it was approved also the use of two liposomal antracyclines, 
the ADM and the DNM-L, which have an objective response rate between 25 and 79%. 
Comparing the DNM-L with AB, the first drug shows the same objective response rate of 
15%, also with a severe leucopoenia, consistently higher if compared with 
polichemotherapy. 
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In patients with pulmonary Kaposi Sarcoma, the DNM-L, 60 mg/m, shows an objective 
response rate of 32% with a quick symptom regression in about 70% of patients. 
The most frequent toxicity remains the neutropoenia, documented among 85% patients. 
Based on these data, the liposomal antracyclines and especially the ADN-L are, at the 
moment, the golden standard in first line chemotherapy for treating Kaposi Sarcoma. 
The vinorelbine, 30 mg/m2 , administered twice a week induces 43% objective responses 
with a rate of complete remissions of 9%, but it also causes severe leucopoenia in 45% of 
the patients (138). 
Therefore, the HAART is an essential therapeutic strategy in Kaposi Sarcoma /HIV AIDS 
patients. It could be used as single anti neoplastic therapy in first stage disease, or with a 
slowly proliferative disease, with a little tumour load and/or when the growth is compatible 
with the long latency of the HAART anti neoplastic activity. Out of the antiretroviral drugs 
advisable for Kaposi Sarcoma patients we can find Protease Inhibitors and especially the 
Indinavir. 
 
In patients with rapid proliferative disease, the golden standard is the chemotherapy alone 
or in association with the antiretroviral therapy (based on the patient tolerability) with 
HAART in the follow up. The liposomal antracyclines are the golden standard among the 
antiblastic drugs, as first line chemoterapy, while the BV/ABV regimens could be 
considered a good choice for patients with reduced marrow reserve.  
A salvage chemotherapy must consider the use of Taxole and vinorelbine, this one for 
patients with poor general conditions. Finally, it is always useful to perform the prophylaxis 
of Pneumocystis Carinii pneumonia in patients with CD4+ count < 200. 
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The DREAM Program 
DREAM (Drug Resource Enhancement against AIDS and Malnutrition) is the Community 
of Sant’ Egidio Program to fight AIDS in Sub Saharian Africa,  a total-approach program 
for treating the disease. It has been active in the field since March 2002, after two years of 
preparation work. The Program has an innovative approach, including anti-retroviral 
therapy, in developing Countries, as institutional partner.  The Community of Sant’Egidio 
has a long history in Mozambique, from the humanitarian aid sent in the early 1980s to the 
official mediation between the guerrillas and the government leading to the General peace 
agreement signed in Rome on 4 October 1992 after 27 months of negotiations. Today, 
Mozambique is a major example of democratic rebirth in sub-Saharan Africa. This special 
link with Mozambique has led the Community of Sant’ Egidio to choose this country as the 
first where to pilot the DREAM Program. 
 
The HIV/AIDS pandemic 
Starting in the early 1980s, AIDS had a development without comparison in the history of 
human pathologies. The tens of millions of people stricken in every country in the world 
bear witness to a pandemic that can truly lay claim to being the first pathology of the era of 
globalization. A radically new situation such as this requires radically new responses. 
Models must be identified that take into account both the features of the illness and the 
available possibilities for treatment. More than two thirds of those with HIV/AIDS – tens of 
millions of people – live in Africa. And only a very small number of these people, mostly 
those with some economic means, have access to antiretroviral treatment. With such a 
serious emergency, while intervention must be quick, what is needed immediately is to 
start laying the foundations for building a medium- and long-term response. 
 
The antiretroviral therapy 
The advent of HAART (Highly Active Anti-Retroviral Therapy) in the mid-1990s radically 
changed the natural history of the illness, transforming AIDS into a chronic pathology. But 
at the same time, antiretroviral therapy created new needs. To yield optimum results, this 
therapy requires technologically advanced monitoring and diagnostic methods, and must 
reach the population extensively, where it lives. The availability of highly specialized 
centers must be combined with the greatest possible spread and accessibility. Here is the 
first contradiction – one apparently difficult to solve, because the impact of the therapeutic 
intervention can only be limited. In brief, here lies the challenge: treatment with 
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antiretroviral drugs must be based on advanced diagnostic methods, by necessity 
localized in a large city; at the same time, to be effective, treatment has to rely on 
extensive distribution. Over time, it became clear that AIDS could not be fought with 
prevention alone; treatment was needed as well. Ongoing prevention is as necessary as 
ever, but on its own, it is clearly not enough. In fact, the lack of hope for access to and 
availability of therapy risks drastically to reduce the effectiveness of prevention, thereby 
lowering interest in knowing ones own condition vis-à-vis the infection: awareness with-out 
an available therapy would risk creating the dramatic and unbearable knowledge of a 
premature demise, often preceded by isolation and social condemnation. 
These needs imply wide-ranging economic and political interventions, as well as highly 
articulated and innovative healthcare planning and organization of services. The millions of 
deaths, infected persons, and orphans require immediate intervention, without getting 
bogged down in non-essential preparatory phases. Likewise, however, the emergency 
intervention should be designed from the beginning with a view to developing stable 
facilities capable of waging the battle over the long term. To put it briefly, intervention 
in the struggle against AIDS must be based on immediacy and farsightedness.  
In the DREAM Program, according to WHO guidelines for treatment in resource-limited 
settings, the first-line treatment  consists of nucleoside reverse transcirptase inhibitors 
(NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). Protease Inhibitors 
(PI) are not considered as part of the first-line regimen, though they may be used in the 
event of treatment failure or intolerance of the first-line combinations. There are two basic 
fixed-dose combination regimens available: 
 
AZT  (zidovudine) + 3TC (lamivudine) + NVP (nevirapine) 
or 
d4T (stavudine) + 3TC (lamivudine) + NVP (nevirapine) 
if the patient is anaemic  
 
The zidovudine-containing regimen is preferred both because of its higher genetic barrier 
to mutations inducing viral resistance and- particularly in Mother to Child Prevention and 
Care, the DREAM scheme in pregnancy to prevent the mother-child transmission, 
because there is more experience with the use of this drug. In the event of anaemia (Hb<8 
mg/dl) preference is given to the stavudine-containing regimen. 
The second-line treatment includes the following drugs: 
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Indinavir (IDV)/ritonavir (RTV) 
Nelfinavir (NFV) 
Didanosine (DDI) 
Abacavir (ABC) 
 
HAART is offered to all patients who fulfill the following criteria: 
WHO clinical stage III, IV or 
CD4 cell count < 200 cell/ul3 
CD4 cell count < 350 cell/ul3  and viral load >55.000 copies/ml 
 
To prevent mother to child transmission, HAART is also offered to all HIV positive women 
starting from their 32nd week of pregnancy, irrespective of their clinical, cirological or 
immunological status. Women who do not meet the general criteria to start HAART stop 
the treatment withi n six months of delivery. 
 
In addition to HAART cotrimoxazole prophylaxis is provided to all patients with CD4 cells 
count <  200 cell/ul3. 
 
In case of Tuberculosis disease,  the therapeutic indication is absolute for patients with 
CD4 < 50 cell/ul3, but is conditioned upon the clinical situation for those with CD4 count is 
greater than 50 but less then 200.  When antiretroviral treatment starts being administrated 
to a patient with HIV infection in intensive treatment for TB, there may be paradoxical 
reactions  between anti-TB and antiretroviral drugs (immuno-reconstruction syndrome). 
For this reason it is often preferred to wait for the first two months of anti TB therapy before 
starting HAART. 
 
A public health intervention 
The HIV pandemic threatens the African population, and tens of millions of Africans are 
currently estimated to be HIV -positive. According to UNAIDS recently published data, in 
2004 about 25.4 million adults and children were infected with HIV in sub-Saharan Africa. 
Among them, 13.3 million are women, and the incidence rate is still very high (137). 
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With such figures, a strategy based only on  prevention seems not effective enough, and 
the urgent need for an extraordinary effort to couple prevention with a more widespread 
use of highly active anti-retroviral therapy (HAART) is widely felt. 
During the last few years, this treatment has been increasingly available in Africa (36), 
thanks to financing by international institutions and especially after the introduction of 
generic drugs, which have cut down the costs per patient/year while maintaining clinical 
effectiveness. (47). 
 
It was starting from these assumptions  that the Community of Sant’Egidio developed its 
methodology in the fight against AIDS, the DREAM Program. This horizontal public health 
intervention aims to take action in the various areas of the country. To be quickly operative 
and effective in order to  respond to emergencies,  DREAM has created a bureaucratically 
and administratively streamlined intervention model. This particularly agile system makes it 
possible to maintain administrative costs – including those for non-local personnel, who 
work exclusively free of charge – at a minimum percentage of the overall budget at all 
times. In other words, the whole budget is used exclusively to fund activities in the country.  
 
Day hospital and home assistance 
Antiretroviral therapy is administered to the population through day hospital and home 
assistance activities. In this way, lacking specialized facilities spread throughout the 
territory, the program is allowed to be in direct contact with the population, thereby 
guaranteeing the necessary control over the  therapy. When the people to be treated 
cannot come closer to the possibility for therapy, it is DREAM that brings them closer. 
However, AIDS cannot be combated exclusively with anti-retroviral drugs. It requires a 
more wide-ranging intervention taking into account the person’s overall needs. The 
package of services ordinarily offered to the patient on a stable basis is comprised of 
voluntary counseling and testing, lab tests (biochemistry, haemochrome, CD4+ cells 
count, and viral load), antiretroviral therapy, treatment of opportunistic infections and 
sexually transmitted diseases, nutritional support, basic health education, and social 
support. 
DREAM is also used for the purposes of research in public healthcare, epidemiology of 
services and their impact, in clinics, and in therapy in developing countries. The acquisition 
of new knowledge in research dedicated to development interventions in impoverished 
countries is a sound contribution in the fight against AIDS. In this sense, the program has 
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strong connections with the scientific world and is oriented towards gathering data for 
epidemiological and clinical studies, both as routine and for ad-hoc investigations. 
 
The laboratory 
To be effective, antiretroviral treatment requires strong lab support. This is why the 
DREAM program has included the development of highly specialized molecular biology 
labs, where the CD4+ count and the viral load measurement (in accordance with the 
indications of the diagnostic and therapeutic protocols), in addition to the basic 
biochemistry and haemochrome, are regularly performed, acting as the technological 
core of the whole program. Labs of this kind are needed in order to respond quickly and 
effectively to the development of drug-resistant viral strains. This is an investment for the 
country’s future, both in training highly specialized human resources and in equipment. 
 
Computerization. 
All the DREAM program’s activities are monitored through a computer network linking the 
various centers to one an-other and to the reference labs. This system guarantees efficient 
monitoring of the treated patients – including adherence to the therapy – and becomes an 
important source of data that can be used to continue improving the quality of the 
interventions, through applied research too. And it is applied research that makes it 
possible to perfect the forms of intervention and helps guarantee that the finest, most 
effective help is offered, even in sub-Saharan Africa countries. 
 
DREAM laboratory’s  implementation 
The Laboratories have been developed to monitor the efficacy of the HAART supplied to 
all the patients positive to HIV test and enrolled in the DREAM  Program. In the labs there 
are also instruments and technologies needed to perform all the tests and assess the 
health status of HIV/AIDS suffering patients.  
Two are the main  problems to implementing a laboratory of this kind. One of this is 
certainly related to the diagnostic costs.  Regarding drugs, in fact, an important discussion 
was raised in the past years, which leave to open some possibilities: today generic drugs 
are available, of cleared efficacy, permitting to decrease the costs sensibly.  
About diagnostics, it is no possible to assert the same and this is a real limitation in use    
some indicators as CD4 cells count or the viral load determination in the scaling up, even if 
they represent significant instruments to monitoring therapy. An other important problem, it 
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was the necessity to implement excellent diagnosis  facilities in Central Hospitals in big 
cities, designed with Western standard.  
These two challenges, an economic one and a technical one, we faced and partially won 
opening the two laboratories in Maputo, Beira and Nampula, the Capital, the 2nd  and 3 rd 
cities in Mozambique.  
The lab has been set up according to the safety rules in force in the developed countries. 
All the technicians working in the lab have been accurately trained on the instruments 
functions as well as on the procedure necessary to work safely.  
The people working in the labs are supplied with white coats, gloves, disposable plastic 
ware as well as specific reagents for cleaning and decontaminating the workbenches and 
themselves. 
A laminar flow hood is set up for viral particle treatment avoiding the dispersion of 
infectious film. 
An autoclave supplied with disposable plastic bags sterilizes all the outgoing material (no 
facilities are provided in the Central Hospital to inactivate the lab waste). 
The arrangement of the lab has been realized in order to separate the different analytical 
sections of the lab (haematology/cytometry, serology/biochemistry, molecular 
biology/bDNA). The structure of the building has been exploited as to have an optimized 
working line. It starts when the blood samples arrive and ends with the results output. A 
complete set of cooler/freezers has been set up to preserve the reagents and the plasma 
samples at the right temperature. 
A proprietary software has been developed to archive and manage all the data produced 
in the lab. A network has been built to connect all the labs equipment and to perform 
remote control and validation of the labs working flow.  
 
Cost-reduced analytical methods 
About  cost-reduced technologies, some methods were developed to reduce the analysis 
costs, using methods employing smaller volumes (micro-methods). Also about the 
lymphocyte sub-populations count it was evaluated and adopted a new flow cytometry 
protocol.  
In fact, it is well known that laboratory tests are mandatory for the correct management of 
HAART, and that international guidelines impose specific protocols for CD4 + lymphocyte 
count and measurement of viral load as parameters to guide therapy in HIV-positive 
patients (32). Attempts to use simpler indicators, like the total lymphocyte count instead of 
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CD4 (9, 131) could lead to gross measurement errors in the recruitment and control of 
patients (85). 
 
The need to speed up the spread of health care and diagnostic facilities to fight AIDS (89) 
conflicts with the exorbitant cost of routine tests in the resource-poor settings. Laboratory 
tests recommended by international guidelines are prohibitively expensive most of the 
weak economies in sub-Saharan Africa (100). 
Research has recently been developed to identify less complex yet reliable equipment and 
protocols to be used in resource-limited settings, using micro-volume fluorimetry, 
immunomagnetic systems, cytospheres, simplified flow cytometers or modifying classic 
flow cytometry protocols to obtain reliable CD4 + T lymphocyte counts with simpler 
equipment (10,13, 25, 41, 42, 55, 58, 61, 104) 
However, such alternative strategies did not always meet the major requirement of a 
drastic cost cutting of consumables. Flow cytometric immunophenotyping has been 
evolving with time into unsurpassedly precise and reliable, but increasingly 
complicated and expensive technology (64, 88). 
Fighting AIDS effectively in resource-poor regions is therefore in urgent need of simplifying 
techniques to reduce the costs of reagents and minimize the specialised manpower (72, 
73, 74).  
 
Our effort was to reduce the amount of antibodies needed for a correct determination of 
lymphocyte subsets to monitor HIV + patients and to improve the accuracy of a gating 
technique still based on physical parameters. Recently, the “panleucogating” (PLG) 
protocol has been developed and validated in a number of settings (59).  
Our effort was to corroborate these studies, particularly the one by Pattanapanyasat (114) 
to demonstrate that similar good results can be obtained in different settings, with different 
antibodies, sample volumes, lysing strategies and instruments. 
This protocol is based on a simplified staining procedure using only two antibodies, 
CD45/CD4, and on a CD45-based gating procedure which gives a good discrimination of 
lymphocytes and enables the enumeration of CD4 + cells over the entire white cell 
population without the need for a leukocyte differential count. 
An effective quality control was set up to monitoring the whole complex procedure from 
withdrawal to reporting, to transport and effective use in instrument methods to 
determining diagnostic parameters. 
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MATERIALS AND METHODS 
 
Samples and sampling  
To study seroprevalence of HHV8 in Mozambique in relation with HIV/AIDS, and the 
clinical evidence of Kaposi Sarcoma AIDS related incidence in Mozambique, it was 
considered the whole DREAM cohort in Mozambique. Since the start up in March 2002 till 
the end of 2005, when we started this part of the study, we have enrolled 14.011 HIV + 
patients in the Country, in 8 different health centers in the South and in the Central region, 
9065 females (64,7%) and  4946 males (35,3 %). Half of them started HAART, on the 
base of the international protocols used by the DREAM Program. Like all patients served 
by DREAM, they have access to Community Care and Home Care Services (CCHC): 
counselling, laboratory monitoring, treatment and care (antiretroviral drugs, opportunistic 
infection treatment, nutritional supplement, sexually transmitted infections treatment), 
supply of mosquito nets and health education. At the Health Centre some parameters like 
weight and height were constantly monitored, to determine also the Body Mass Index. 
Based on this value (BMI<18), patients received Nutritional Supplement. 
The diagnosis of HIV+ seropositivity, when performed in the GATV -Gabinete de 
Aconselhamento e Testagem Volontaria- of the Country, was reconfirmed by using rapid 
tests for antibody detection. 
 
To establish the relationship between HAART, chemotherapy treatment and time of 
regression and/or remission we focused the study on the Machava Health Centre, close to 
the capital Maputo, in the South of the Country. We found 61 patients with Kaposi 
Sarcoma diagnosis. The data are referred to 4 years' activity (2002-2006). 
All Kaposi Sarcoma diagnoses were confirmed at the Pathological Anatomy Laboratory-
Central Hospital of Maputo. 
Out of 61 KS patients, 31 patients died (50,8%) and 3 were transferred to other health 
centres. 27 patients are in follow up, being 39 the median age, respectively 15 males 
(56%) and 12 females (44%). 
 
To study HHV8 seroprevalence in HIV positive patients we randomly derived a subcohort 
from the DREAM programme of the Community of Sant’Egidio, particularly those followed 
in the centre of Machava (Maputo), and Beira Mangachingussura, where a home care and 
community care programme, together with HAART treatment for AIDS, is being 
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implemented. 
The samples were randomly collected from the two centres among the patients included in 
the Programme and the subcohort was made up of adults on antiretroviral therapy. It 
consisted of 161 patients, 93 (57.8%) women and 68 (42.2%) men. The average age of 
the sample was 31.54, with a median equal to 31.81. In the HIV positive subcohort, HIV1 
viral load was measured and the immune status (CD4+ and CD8+ T lymphocytes count) 
was studied. 
 
To study the general HHV8 seroprevalence in Mozambique we needed HIV negative 
patients. So, the HIV-negative subcohort (n=166) was made up of people admitted into the 
“Hospital Central de Maputo”, chosen for having similar personal data to the HIV-positive 
cohort. The average age of the sample was 30.44, with a median equal to 31.0 with a 
minimum of 0 and a maximum of 57. The sex distribution was 69 males (41.6%) and 97 
females (58.4%). The few children included in the studied population were tested positive 
because of the presence of maternal antibodies (two children under the age of 18 months 
in a HIV-negative population, included and tested because their data were noted but not 
associable to either cohort), while the results of children older than 18 months were 
interesting. Unfortunately, it was not possible to find out if they were children of women 
testing positive for HHV8. This information would have been interesting because children 
of women testing positive for HHV8 appear to be more frequently positive to the virus 
(117), and there is even speculation of a mother-to-child transmission.  
The HIV screening was performed with rapid tests for HIV 1 and 2 antibody detection. 
Finally, to study HHV8 prevalence, the cohort included 327 Mozambican patients, 137 
males (42%) and 190 females (58%), median age 31. Among them, 161 were HIV-positive 
and 166 HIV-negative. 
 
Testing 
HIV screening was performed in the DREAM Center. Only for the HIV negative subcohort 
the sera were collected from hospitalized patients  in the Hospital Microbiology Laboratory 
and tested in the DREAM Laboratory. 
Immunophenotyping, viral load and HHV8 screening were performed in the Central 
Hospital DREAM Center. PCR researches were performed in Tor Vergata University 
(Roma, Italy) Public Health Department  Laboratories, after DNA extraction.   
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It is noticeable to consider that almost all the experimental work of the project was done in 
the Laboratory of Molecular Biology of Maputo Central Hospital (Mozambique). 
Once collected by venipuncture at the DREAM Center in a red cap tube for biochemistry or 
in a violet cap tube containing EDTA as anticoagulant, blood was stored at room 
temperature (but in a conditioned 25°C room) and quickly transferred to the Central 
Hospital DREAM Laboratory. Blood is normally transported on the same morning to the 
laboratory in slightly refrigerated insulated containers. In lab, plasma aliquots were 
separated and stored in a – 80°C freezer for viral load quantification and HHV8 screening. 
Fresh whole blood was used to determine haemograms, since haemoglobin levels are 
particularly significant for the immediate monitoring of the health state of the patient,  and 
CD4 count was performed within few hours.  
Specimens were always forwarded with a form containing at least the case clinical history 
record number, name of the patient, provenance, signature of the director of the Health 
Center, number of vials collected from each patient. 
The Reception office checked that the number of vials corresponded to what declared and 
that they were all labeled. 
Using the appropriate laboratory software, a progressive number was assigned to each 
specimen and this number was attached to the specimen and written on the 
accompanying form. Thus the specimen would be unequivocally identified throughout its 
life in the laboratory and the patient’s privacy guaranteed. 
 
Antibody detection for HIV 
The diagnosis was performed according to the Mozambican national protocol, using a pair 
of rapid tests, the Abbott Determine and the Trinity Biotech Unigold. These are tests in 
lateral flow paper chromatography, easy to perform, rapid and simple to read. Therefore, 
they allow the highest effectiveness in this delicate phase of approaching the patient, 
giving a response within 15’ and avoiding the need for recalling the patient who could have 
objective difficulties to come back for the response (difficult, absent or excessively 
expensive transportation for the majority of people etc). For this reason the test was 
performed at the Health Centre by especially trained nurses. Test sensibility and specificity 
are 99,75% and 100%  for Determine and both 100% for UniGold.  
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Quantification of HIV1 viral RNA.   
The determination of HIV1 viral load was performed with Bayer bDNA method. It is a well-
known, standardized method, adopted in the country for its simplicity of execution and 
management.  
This method has the advantage of being based on amplifying the signal and not the target 
as with the methods using PCR (polymerase chain reaction), thus being less susceptible 
to the problem of contamination. Currently, the bDNA system appears to be the one that 
offers the greatest coverage for the various extant HIV subtypes. Furthermore, bDNA is 
not subject to the errors that are typical of the PCR procedures (amplification of 
contaminant RNA, mutations induced by the polymerase). This results in a reduced level 
of sterility necessary for the analyses to be performed.  
 
Direct research of the HHV8 virus by qualitative PCR .  
The direct research of HHV8 virus is the oldest way to detect it, as shown in the first 
studies, i.e. Withby in 1995. 
La Duca (80) reports the isolation of HHV8 with PCR from plasma with a gain equal to 7%, 
while a higher gain is obtained from lymphocytes (46%). 
Some authors used PCR, specifically researching the ORF 21 region, which is 
characteristic of the lytic phase (tertiary lytic gene, as defined by  Richard G Jenner). 
In a first step of the work, direct extraction and amplification of the HHV8 virus from 15 
plasma samples was tried. Samples were collected from HHV8- HIV positive patients, with 
no clinical evidence of Kaposi Sarcoma. None of them was under antiretroviral treatment.  
The DNA was extracted in Tor Vergata University Laboratories from frozen samples with 
Qiagen-QIAamp MinElute Virus kit  - final volume 30 µl. Qualitative PCR was then 
performed in search of the ORF21 region (lytic phase) as a characteristic of HHV8, using 
two positive and one negative controls. it was not possible to isolate the HHV8 virus over 
15 frozen plasma samples. Several difficulties have been faced. First of all, the probably 
least suitable matrix, the plasma used for the need of exploiting the existent serum bank. 
In addition, sending frozen samples from Sub Saharan Africa is very expensive and not so 
easy. For this reason, it was chosen to change the method to screen the cohort, because 
PCR was not available in Mozambique at the moment, and collecting materials from 
lesions in Kaposi Sarcoma patients was not authorized. 
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 HHV8 antibody detection  
Among the methods reported in literature for determining the presence of HHV8, there is 
the detection of latent antigens (LANA), which can be seen with Western Blot or 
immunofluorescence (IFA) and the detection of antigens of the lytic phase like, for 
example, EIA methods to determine the seroprevalence and the antibody titre of the 
antigenic peptide deriving from the ORF 65 region. 
In this study, detection of anti-HHV8 serum antibodies was performed by means of  a 
Biotrin immunohistochemical method (ELISA) for IgG titration. The kit is based upon a mix 
of synthetic peptides capable of detecting the antibodies against HHV8 viral lytic proteins. 
It is an immunoenzymic titration. The specifically bound antibodies are detected through 
an anti-human IgG-based conjugate labelled with peroxydase, and through a substrate 
reaction. The use of lytic peptide epitopes  derived from different viral proteins guarantees 
both high sensitivity and specificity. There is no detectable cross-reactivity with HIV.  
Serum was used in the assay.  
 
Immunophenotyping for the determination of CD4+ and CD8+ T lymphocytes 
To study the immune status and to perform CD4 and CD8 T lymphocytes count,  we used 
the Beckman Coulter EPICS XL-MCL flow cytometer, in double platform, with lyse no 
wash method and Beckman monoclonal antibodies. A big effort was made in order to 
optimize the diagnostic protocols for CD4 and CD8. The idea was to use the most possibly 
efficient protocol. As a matter of fact, the major obstacle to the diffusion of a Western-type 
anti-HIV strategy is presently the exaggerate cost of routine diagnostics. The type and 
number of specialized tests suggested by the international guidelines has actually 
unaffordable costs for most economic systems of the Sub-Saharan countries (100) 
Therefore, the research of application protocols allowing to get the needed information 
with a reduction of the number of tubes and antibodies needed for a correct determination 
of lymphocyte sub-populations is an answer to such an issue. Recently the 
‘PanLeucogating’ protocol has been developed and validated; it is based on a strategy of 
simplified labelling with only two antibodies, CD45 / CD4, and on a gating procedure which 
allows a good resolution of the CD4+ lymphocytes without the necessity of leukocyte 
formula. 
The PanLeucogating (PLG) has been compared with the protocol commonly used in 
several countries, based on the use of three antibodies CD3, CD4 and CD8 (99), and 
definitively adopted. 
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The comparison study was performed on 189 samples. All the HIV-positive patients were 
included in the DREAM program and were on antiretroviral therapy. Among them, 30 
subjects (15.8%) had less than 200 CD4/µL. 
The comparison study was carried out using a random selection of HIV + clinical samples 
from various peripheral health centers which sent materials for routine analyses to the 
hospital facilities. The HIV-positive status of patients had been assessed. Three mL of 
peripheral venous blood were taken from each patient in BD Vacutainer K 3 EDTA tubes. 
The samples were processed within 24 hours from collection. 
The antibodies used for routine analysis were Beckman Immunotech Trio-Opticlone 
premixed anti-CD4( FITC) / anti-CD8(PE) / anti-CD3(PCy5). For the PLG technique a 
volume/volume mixture of anti-CD45(FITC) and anti-CD4(PE) Beckman Immunotech was 
used. When requested by clinicians, anti-CD8(PCy5) Beckman Immunotech was added to 
PLG. Both techniques were carried out with a lyse-no wash method with an ammonium 
chloride buffer. 
The sample preparation procedure was the following: 50 µL of whole blood were added to 
5 µL of the Trio-Opticlone mixture in one tube and to 5 µL of the PLG mixture in the other 
one. The test tubes were incubated in the dark at room temperature. After 30 minutes, 1 
mL of lysing solution (generic lysing buffer) was added. The test tubes were incubated for 
another 20 minutes in the dark. The samples were then directly processed in the flow 
cytometer within one hour. Visual confirmation of a complete Red Blood Cells (RBC) lysing 
was requested to technicians. A Beckman Coulter EPICS XL MCL (with Multi Carousel 
Loader) flow cytometer equipped with an Argon ion laser (488 nm wavelength) was used, 
allowing the simultaneous measurement of four fluorescence channels. The routine 
protocol was based on the identification of lymphocytes by physical parameters, through a 
homogeneous lymphocyte gate on a Forward Scatter (FS) vs Side Scatter (SS) dot plot. 
Within the lymphocyte gate, the percentage of double positive elements CD3-PCy5 / CD4-
FITC and CD3-PCy5 / CD8-PE, respectively, was calculated. The percentage of CD3 + 
CD4 + cells and CD3 + CD8 + cells was related to the total lymphocyte count obtained by 
the hematology analyzer, in order to give the absolute number of CD4 + and CD8 + per 
µL. With PLG the percentage of CD4 + (and of CD8 + cells if requested) over all 
leucocytes  identified by CD45 was calculated, and CD3 expression was not taken into 
account. 
Briefly, in a CD45 vs SS display, total leucocytes and lymphocytes are identified by two 
different gates. The cytometric percentage of lymphocytes over the total White Blood Cells 
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(WBC) can be calculated. In another display, the percentage of CD4 (or CD8) positive 
elements is extracted from total leucocytes. Using the total WBC count per µL from the 
hematology analyzer, the absolute CD4 + (or CD8 + ) cell count is then calculated. The 
CD4/CD8 ratio is also available if the CD8 value is requested by the clinician. In the PLG 
protocol, however, CD8 + cells must be identified as CD8 +high CD45 high SS low cells 
only, to  avoid the inclusion of CD8 +dim lymphocytes that are mostly CD3 - . The 
lymphocyte subsets count was carried out in dual-platform mode using a hematology 
analyzer Sysmex K21N, which gave the absolute lymphocyte count to be used in routine 
analysis, or the total white blood cell (WBC) count, to be used in the PLG.  
 
Statistical analysis 
All the clinical and haematic informations were registered using the DREAM Prog. 
Software, a proprietary software developed to manage the clinical process of each patient. 
All the visits were managed using the DREAM Prog. The software registers the following 
information: 
folder ID, personal data, social information, visits (anamnesis, symptomatology, BMI, drug 
prescriptions),  blood exams, appointments (examination, drugs, blood collection, 
medication, food integration, check, HIV test, “verify”), aids stage (international 
classification), kind of service, ARV therapy, date of record registration. 
In order to describe the HHV8 prevalence and to determine the significance of HHV8 
infection versus CD4 and viral load levels, and versus the BMI and Hb levels,  SPSS 
software for statistical calculus was used. 
To evaluate the PLG Protocol, statistical analysis was carried out by linear regression and 
Bland-Altman analyses. Statistical analysis was carried out using Kaleidagraph 3.5, 
Synergy Software. Percent and absolute values obtained from the two methods for CD4 
and CD8 respectively were plotted. Linear regression analysis was used to calculate 
squared R. To compare the two different gating strategies, the differences of the pairs 
CD4%(PLG)-CD4%(Trio), CD4(PLG)-CD4(Trio) and CD8%(PLG)-CD8%(Trio) 
respectively, CD8(PLG)-CD8(Trio) were plotted against their average as  already reported. 
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RESULTS 
 
First of all, we’d like to show the results in defining the cost-effective protocol to monitoring 
CD4 and CD8 count in the studied population. The following tables illustrate the PLG 
protocol versus the Trio one. 
The table 1 shows the regression parameters of CD4+ and CD8+ values, in percentage 
and in absolute count (abs), obtained with the PLG and the Trio protocols, respectively. 
Absolute counts were obtained using total WBC count (PLG) or lymphocyte count (Trio), 
respectively. In column B a cut off of clinical interest has been applied to %CD4+ and 
CD4+ absolute count. 
 
Tab. 1 
A B slope intercept R2 R 
%CD4(PLG) vs 
%CD4(Trio) 
 0,954 1,52 0,964 0,982 
 
%CD4(PLG) vs 
 %CD4(Trio) <15% 
0,812 3,046 0,689 0,830 
 
%CD4(PLG) vs 
 %CD4(Trio) >15% 
0,947 0,920 0,947 0,973 
abs CD4(PLG) vs 
CD4(Trio) 
 0,965 27,6 0,976 0,988 
 
abs CD4(PLG) vs  
CD4(Trio) <200/µL 
1,075 0,038 0,900 0,948 
 
abs CD4(PLG) vs 
 CD4(Trio) >200/µL 
0,966 27,196 0,972 0,986 
%CD8(PLG) vs 
%CD8(Trio) 
 0,972 1,8 0,970 0,985 
abs CD8(PLG) vs 
CD8(Trio) 
 0,968 58,4 0,988 0,994 
 
 
 
 
 32
In table 2 statistical parameters obtained with Bland-Altman analysis of CD4+ and CD8+ 
values, are shown in percentage and in total count. They are obtained with the PLG and 
the Trio protocols, respectively. In column B a cut off of clinical interest has been applied 
to %CD4+ and CD4+ total count. 
 
Tab.2  
  mean diff median dev st lo.lim. up.lim. 
%CD4(PLG)-
%CD4(Trio) 
 -0,39 -0,07 2,69 -5,65 4,89 
 
%CD4(PLG)- 
%CD4(Trio) <15% 
-1,21 -0,20 2,39 -5,89 3,57 
 
%CD4(PLG)- 
%CD4(Trio) >15% 
-0,02 0,0 2,74 -5,39 5,36 
CD4(PLG)-
CD4(Trio) 
 -7,50 -2,24 61,22 -127,50 112,50 
 
CD4(PLG)- 
CD4(Trio) <200 
-9,14 -2,49 21,12 -50,53 32,25 
 
CD4(PLG)- 
CD4(Trio) >200 
-7,17 -2,00 66,45 -137,42 123,07 
%CD8(PLG)-
%CD8(Trio) 
 -0,45 -0,60 2,54 -5,43 4,54 
CD8(PLG)-
CD8(Trio) 
 -23,44 -17,70 71,67 -164,42 116,54 
 
In the fig.1 it is possible to see the regression lines of CD4+ and CD8+ values, in 
percentage and in absolute count (abs), obtained with the PLG and the Trio protocols, 
respectively. Absolute counts were obtained using total WBC count (PLG) or lymphocyte 
count (Trio), respectively. The R value are reported on the top of each panel with the 
regression equation. 
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FIG.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the fig. 2 we can observe the Bland-Altman analysis of CD4 + and CD8 + . The 
difference of the values, in percentage and in total count, obtained with the PLG and the 
Trio protocols, respectively, have been plotted against the average of the same values. 
The mean difference of each panel is reported 
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FIG. 2 
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The following tables  illustrate our results about seroprevalence of HHV8 in Mozambique in 
the population and in relation with HIV/AIDS. 
In this figure 3 we can compare  the HHV8 prevalence registered in our study and the 
HHV8 prevalence in some other Countries in Sub Saharan Africa. Mozambique is well 
placed in the area context, with a seroprevalence among the total population equal to 
51.07%, overall higher than that registered in Zambia in a similar cohort and close to that 
registered in Malawi, two countries bordering Mozambique to the north and with similar 
populations and socio-economic situations 
 
 
 
 
 
In Tab.3 are listed our data about prevalence of HHV8 in Mozambique, in comparison with 
the Malawian, Zambian and South African cohorts. In Mozambique the HHV8 prevalence 
is about 51 %  
 
COUNTRY SEROPREVALENCE 
MALAWI (cohort of hospitalised people) 67% 
MALAWI (cohort of healthy volunteers) 54% 
ZAMBIA (cohort of HIV+/- pregnant women) 51,1% 
ZAMBIA (cohort of HIV- pregnant women) 48,8 % 
SOUTH AFRICA (hospitalised, adjusted by age and sex) 30% 
MOZAMBIQUE (cohort of HIV+) 52,7% 
MOZAMBIQUE (cohort of HIV -) 49,4% 
MOZAMBIQUE 51,07% 
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In Mozambique: 51% of HHV8 positive persons. 
 
 
 
Analysing the cohort and considering the HIV positivity, we can divide the population in 
two subcohort, the HIV positive, with a HHV8 prevalence of 52,7%, and the HIV negative 
with HHV8 prevalence of 49,4%. 
 
 
 
 
 
 
 
HHV8  in Mozambique
HHV8 + 
HIV POSITIVE
HHV8 +
HIV NEGATIVE
HHV8 +
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In this table 4  we have the results obtained in our  two sub population, HIV positive and 
HIV negative patients: around half (52.7%) of the HIV -positive population turned out to be 
positive to HHV8 too, and around 49,4 % of the HIV-negative population tested positive for 
HHV8, a very similar percentage 
 
 
 
Results Frequency percentage 
HIV positive   
HHV8 negative 76 47,2 
HHV8 positive 85 52,7 
TOTAL HIV positive 161 100,0 
HIV negative   
HHV8 negative 84 50,6 
HHV8 positive 82 49,4 
TOTAL 327  
 
 
Tab 5 shows the HHV8 prevalence in the  studied population described by sex ratio and 
median age. The median age is about 31 years in the both groups. Female ratio in about 
58%. 
 
 
 
Results Female % Age median Frequency 
HHV8 pos 57,8 31,8 161 
HHV8 neg 58,4 31,0 166 
TOTAL 58 31,0 327 
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In following tables we show some information about the HIV positive cohort, which is a part 
of the DREAM population.  
 
 
In Tab.6  HIV positive cohort is studied per age median and sex ratio statistical 
significance, in HHV8 negative and HHV8 positive group. 
 
HIV + Age Median Sig. Female % Sig. 
HHV8 Neg 31,8 0,779 58,4 ,549 
HHV8 Pos 31,0 0,779 57,8 ,549 
 
 
There is not significance of HHV8 infection per age  (p=0,779) or per sex (p=0,549) in HIV 
patients. 
 
 
 
Tab 7 shows the HIV positive cohort, describing by CD4 and CD8 count levels and viral 
load. Significance of HHV8 infection in CD4, CD8 and viral load was studied. 
 
 
 HHV8 Mean 
Std. 
Deviation 
Sig. 
CD4 neg 452,81 354,992 ,044 
 pos 580,32 432,849 ,044 
 Total 516,12 387,968  
CD8 neg 790,68 447,818 ,001 
 pos 1237,11 1031,836 ,001 
 Total 1012,90 808,787  
VL Neg 44755,54 103097,625 ,766 
 Pos 39692,31 83870,535 ,766 
 Total 40944,16 90070,027  
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In the HIV positive cohort we registered a statistical significance in CD8 absolute value, 
comparing the HHV8 positive and HHV8 negative group (p=0.001). Not significance is 
observed for CD4 absolute count value, and viral load log10 value. 
 
The Tab 8 illustrates in the HIV positive cohort the Body Max Index values and 
Haemoglobin levels.  Significance of HHV8 infection in BMI and Haemoglobin levels was 
studied. 
 
HHV8 MEAN 
Std. 
Deviation 
Sig. 
BMI Neg 21,8063 3,6173 ,951 
 Pos 20,6069 3,8605  
Hb neg 10,937 2,3863 ,035 
 pos 10,460 1,9249  
 
In the HIV positive cohort we observe no statistical significance regarding Body Max Index 
values, but a significance in Haemoglobin levels between HHV8 negative and HHV8 
positive group. The mean value is 10,9 g/dl for HHV8 negative patients and 10,5 g/dl for 
HHV8 positive patients, with a difference of 0,4 g/dl. 
 
After measuring the HHV8 prevalence, we studied the Kaposi Sarcoma incidence in 
Mozambique, considering the DREAM cohort and then working only with the Machava 
Centre data, for a period of 4 years. 
 
The total incidence is 25,2 °/°°,   
 
KAPOSI SARCOMA IN DREAM COHORT
14.011
353
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TAB 9 
In the next  table (9) we can observe the Kaposi Sarcoma incidence in the DREAM 
population since the start up in March 2002, until the end of the study, December 2006. 
The total incidence is 25,2 °/°°,  but important differences are registered  among the 
different Health Centres. 
 
 
 
HEALTH CENTRE KS cases number All patients incidence °/°° 
Quelimane (Zambesia) 70 906 77,3 
Mangachingussura (Sofala) 20 1060 18,9 
Chokwe (Gaza) 131 3890 33,7 
Benfica (Maputo) 14 920 15,2 
Machava (Maputo) 61 2246 27,1 
Mahotas ** (Maputo) 2 194 10,3 
Matola * (Maputo) 4 1374 02,9 
Polana Canico (Maputo) 51 3421 14,9 
TOTAL 353 14011 25,2 
 
* only MCPC 
   
** Health Centre with 
Paediatric Assistance 
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In this table 10, we can observe the sex and age distribution in the DREAM Cohort and in 
the group of patients with Kaposi Sarcoma diagnosis. About the 353 patients with KS,  all 
classified as 4th WHO level, 279 of them are females (79,1%) and  74 males (20,8). 
 
Tab.10  
 
 
 
In table 11 we compare the immunological and virological state of HIV positive patients 
with Kaposi ‘s Sarcoma and the HIV  positive whole cohort (DREAM cohort). Of course, 
also the patients with sarcoma are part of the DREAM cohort but only for this study we 
analyse the data separately. Patients with Sarcoma have CD4 count and viral load levels 
baseline worse than the whole cohort. This is normal, because the Sarcoma is one of the 
 
Patients 
number 
Female % 
Female 
median age 
Male median 
age 
Sig. 
DREAM Cohort 14.011 
64,7 
(C.I.1,004) 
32 35,44 P<0,001 
Confirmed Kaposi 
Cohort 
353 
79,1 
(C.I.3,23) 
38 40 P<0,001 
0
10
20
30
40
50
60
70
80
QL MN CK BF MC MH MT PC
KAPOSI SARCOMA INCIDENCE 
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diseases that classify patient in the 4 th stage. It is a signal of important compromising of 
the patient’s state.  
All the patients considered here are under antiretroviral treatment. After 6 months we 
observe in both the group a good viral response. In fact, viral load is undetectable in the 
Kaposi Sarcoma cohort and also in the DREAM cohort. About immunological state, we 
observe that both groups show an improvement, higher in the DREAM cohort, with CD4 
increase of +124,5%, than the Kaposi Sarcoma group, whose improvement in CD4 count 
is only of 39,8 %. 
 
 
Tab 11 
  
 KS cohort baseline DREAM cohort baseline 
CD4 188 cell/ul3 155 cell/ul3 
viral load 55.000 copies/ml 15.600 copies/ml 
 
 
 
 
 KS cohort on treatment after 6 months 
DREAM cohort on treatment 
after 6 months 
CD4 263 cell/ul3 348 cell/ul3 
viral load <50  copies/ml <50 copies/ml 
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Among patients with Sarcoma, we could distinguish two different subgroups. (tab 12) One  
was treated also with cytostatics while the other wasn’t. Regarding immunological 
improvement, the first group, A, show only a little gain (7,8%); the group B gain is better, 
39,3%. 
 
 
CD4
0
100
200
300
400
1 2
KS COHORT DREAM COHORT
VIRAL LOAD
0
10000
20000
30000
40000
50000
60000
1 2
KS COHORT DREAM COHORT
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Tab 12 
 
CD4 median 
value 
with cytostatics (A) 
7,8% 
without cytostatics (B) 
39,3% 
baseline 296 cell/ul3  188 cell/ul3  
after 6 months  
319 cell/ul3 
 
 262 cell/ul3 
 
 
yes
no
baseline
after 6 months
0
50
100
150
200
250
300
350
cytostatics
cell/m3
CD4 median value
 
 
 
In the next table 13, we considered surviving patients with Kaposi Sarcoma coming to the 
Machava Center. We listed the initial diagnosis of Sarcoma, compared with time of 
disease remission, in group treated also with cytostatics (A, 15 patients) and the untreated 
group (B, 12 patients). It was not easy to determine the real point in which the sarcoma 
disappeared. We considered the point being the date when in the data-base reported the 
physician’s note “asymptomatic”  after several visits where they appoint the diagnosis of 
Sarcoma. In the treated group A 8 patients became asymptomatics (53%) and in the 
untreated group B 10 patients (83%).  
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Tab  13 
 
SARCOMA 
LOCALIZATION 
INITIAL 
DIAGNOSIS IN 
SURVIVAL 
PATIENTS 
WITH KS 
INITIAL 
DIAGNOSIS 
IN A GROUP 
PATIENTS 
A GROUP 
PATIENTS BEEN 
ASYMPTOMATICS 
INITIAL 
DIAGNOSIS 
IN B GROUP 
PATIENTS 
B GROUP 
PATIENTS BEEN 
ASYMTOMATICS 
CUTANEOUS 8 3 3 5 4 
LIMBS 14 9 4 5 3 
PALATE 3 2 - 1 2 
SCATTERED 2 1 1 1 1 
TOTAL 27 15 8 12 10 
 
 
 
 
0
1
2
3
4
5
6
7
8
9
Cutaneous Limbs Palate scattered
Sarcoma localization
 with cytostatics T0
with cytostatics Tend
without cytostatics T0
without cytostatics Tend
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Now we compare the surviving patients and died. 
 
deaths/survivals
47%
53%
 
 
In this table 14, we compared the immunological and virological state of died patients 
versus surviving patients. There is a statistical significance in the immunological state  
difference. No statistical difference is observed in virological state.  
 
TAB 14 CD4 BASELINE LEVELS  
 
PATIENTS MEDIAN MIN MAX 
SURVIVALS 
(N=27) 
183 1 528 
DEATHS 
(N=30) 
90 1 982 
P<0,0005  
 
 
VIRAL LOAD BASELINE LEVELS (LOG10) 
 
PATIENTS MEDIAN MIN MAX 
SURVIVALS 
(N=27) 
4,7099 0,0 5,6990 
DEATHS 
(N=30) 
5,0374 1 5,6990 
p>0,005  
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Patients surviving have CD4 count higher than the patients died, and lower viral load 
baseline.  
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DISCUSSION 
 
First of all, it is important to illustrate the optimisation in setting the Laboratory to obtain all 
the needed parameters, especially immunophenotyping, because this is a very important 
contribution from Pisa University and the Department of Oncology, Division of Surgical, 
Molecular and Ultrastructural Pathology.  
 
The limitation of the strategy based on lymphocyte FS vs SS gate lies in the inaccurate 
identification of lymphocytes, especially in the presence of small monocytes and cell 
debris, which causes a variable degree of lymphocyte gate purity. On the contrary, in the 
PLG technique the panleucocyte marker CD45 displays a different quantitative expression 
among the various white blood cell types, which is used to accurately define leucocyte 
population along with their respective SS features. Lymphocytes are thus defined by a 
bright CD45 expression and a low side scatter (CD45 high SS low ). The PLG gating 
strategy including CD8 causes a slight underestimation of the CD8 + cell subset and a 
higher CD4/CD8 ratio compared to the most credited high-technology methods that 
include CD3 staining.  
 
 We can observe table I summarizing the parameters of the regression lines obtained by 
comparing the percentage and absolute values of CD4 + and CD8 + , respectively, 
calculated with both protocols. In column A, the  comparison between CD4% values 
obtained by TRIO and PLG shows an excellent correlation, with R 2 =0.964. Also the 
comparison between CD4 absolute value with the two methods is excellent with R 2 
=0.976. As for CD8, percent comparison between TRIO and PLG shows R 2 =0.970. 
Absolute value comparison shows R 2 =0.988. 
 In the same table, in column B, the parameters of CD4 + regression, both on percentage 
and absolute data, have been analysed using cut off points of 15% and 200 CD4 2 /µL 
respectively, which clinicians consider as critical boundaries for HIV + patient 
classification. 
The same parameters obtained in the CD4 <15% group were R 2 =0.689 and in the CD4 
>15% group R 2 =0.947, respectively.  
 
Figure 1 (a, b, c, d) depicts the correlations obtained by comparing CD4%, CD8%, CD4/µL 
and CD8/µL values obtained with the two protocols. The overall correlation between the 
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results obtained by the two protocols was satisfactory, with R always > 0.96. The 
correlation parameters in the subgroup with CD4 percentage <15% were worse than in the 
subgroup with CD4 + > 15% (R = 0.83). 
Bland-Altman analyses are set out in Figure 2 (a, b, c, d), and the respective statistical 
parameters are summarized in Table II.  
 
Both in the CD8 + % and CD8 + /µL comparisons the mean differences (bias) are 
negative, indicating a systematic underestimation of CD8 + cells with PLG. Column A 
summarizes statistical parameters for CD4 and CD8 percent and absolute value. The 
mean range difference is between -0.39 and -23.44 and the dev. standard range between 
2.54 and 71. Column B illustrate the CD4% and the CD4 absolute value group stratified 
into the two clinical cut off values, 15% and 200 cell/µL respectively. The mean difference 
range is -0.02 and -9.14, dev. st. range is between 2.39 and 66.45. 
 
 The Bland-Altman stratified comparison of the two methods showed that when CD4 + 
cells were <15% a sizable negative bias was present, whereas when CD4 were >15% the 
two methods tended to overlap. This is a further confirmation of the counting inaccuracy 
introduced by the morphologic gating approach. CD8 absolute values also had a negative 
bias, and an high intercept, even if in presence of good R 2 values. 
Moreover, in the CD4 <15% group the unsatisfactory agreement between the two 
analytical methods was also associated with a poor regression analysis (R 2 =0.689), thus 
confirming the bias introduced by the morphological gate. Indeed, the usage of CD8 
without CD3 in the PLG protocol can be considered as an acceptable compromise 
between the availability of clinically relevant information and the need to contain costs, 
also considering the new trend by physicians that avoid to request CD8 determination.  In 
the PLG protocol CD8 + cells must necessarily be identified as CD8 +bright only, to avoid 
the inclusion of CD3-neg CD8 +dim elements. This causes a systematic underestimation 
of percent and absolute CD8 + cells of variable magnitude, which explains the persistently 
negative bias when PLG-derived CD8 + cell counts are compared to the CD3-based 
routine method. 
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HHV8 prevalence in Mozambique 
About the first goal of the study, HHV8 prevalence in Mozambique, the obtained  results in 
the whole studied cohort (HIV+/- patients) showed that the HHV8 prevalence is very close 
to the one measured by other Authors in the  area. Our data measured a prevalence of 
51,07%, like in Zambia (51,1%)  in a similar cohort  of HIV+/- pregnant women, and in 
Malawi (54%) in a cohort of healthy volunteers (HIV status unknown) A lower percentage 
is registered in South Africa (30%). (Tab.3) 
As can be seen, (Fig3), in Mozambique the HHV8 distribution is the same as in Zambia 
and Malawi, two countries bordering Mozambique to the north and with similar populations 
and socio-economic situations.  
The results obtained in the two population groups are listed in table n.4: around half 
(52.7%) of the HIV-positive population turned out to be positive to HHV8 too, and around 
49,4% of the HIV-negative population tested positive for HHV8, a very similar percentage.  
 
In table n.5 the prevalence of HHV8 in the total studied Mozambican population described 
by sex ratio and median age.  The median age is a little lower than the measured one in 
the whole DREAM cohort, sex distribution is very similar. 
There isn’t any influence of sex and age in the HHV8 positivity, the two groups result 
homogeneous by age  and sex. . (tab 6) 
 
 Let us now consider some variables measured in the HIV positive sub-cohort.  
As already said, for each sample the values of HIV1 viral load and the immunological 
parameters referred to the CD4 and CD8 sublymphocyte populations have also been 
determined. Depending on the reactivity to the ELISA test for HHV8, calculations have 
been made of the mean, with interval of confidence of 95%, standard deviation, standard 
error, minimum and maximum. The table n.7 summarizes the observed data and shows 
the significance referred to the considered variables. It can be observed that statistically 
significant correlation is represented only  by the mean value of CD8+ lymphocytes. 
(p>0,05). In our experience it is important to monitor also Haemoglobin  and BMI levels to 
have a quick and affordable information about the health state of the patient. When 
patients have BMI<18 or Haemoglobin level <8 g/dl their risk of death is increased. For this 
reason, for example, in the DREAM software a warning is active when these parameters 
are low. In the HIV sub cohort all the tested patients have BMI > 18 and no relationship 
exists between BMI and HHV8 positivity.  The difference in Haemoglobin levels (0,5 g/dl) 
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seems to have a statistical (p=.035),  but not clinical  significance. In fact, all the tested 
patients have Hb  > 8 g/dl.  (tab 8) 
 
The immune status seems in some way to be associated with HHV8 seropositivity, in 
relation either with a worse CD4 count, or with an increase of the mean of CD8 in the 
positive group. As known, we note the  CD8+ T cell activation (43).  Even if it is unclear 
how the immune response controls human herpesvirus 8 it seems that specific cytotoxic T 
lymphocytes (CTLs) may provide protection from persistent HHV8 infection. These results 
support the crucial role of cellular immune responses in controlling HHV8 replication, in 
preventing malignancies in latently infected subjects, and in conferring genuine resistance 
to persistent infection.(72 ) HHV8 interacts with the immune system through still unknown 
mechanisms. For example, the role of K3 and K5 in the deregulation of the Class I 
Histocompatibility Major Complex is being investigated (63) 
 
 Kaposi Sarcoma in HIV+ patients under ARV and treated or not treated with 
chemotherapy 
Secondarily, we studied the clinical Kaposi Sarcoma evidence in HIV+ patients under ARV 
and treated or not treated with chemotherapy. 
In the studied DREAM cohort,  (14.011 HIV + patients in the Country) , we found 455 
folder IDs with diagnosis of Kaposi’s Sarcoma. Analysing the data, out of the 455 KS 
cases, only 353 were confirmed (78%). At this level, confirmation is made by the 
physician, by re-evaluating the patient situation and identifying the suspected lesions 
under an other disease  and not KS. In Mozambique, in fact, the Kaposi Sarcoma 
diagnosis is usually only a clinical diagnosis, because anatomo- pathology laboratories are 
available only in Maputo and Beira. Among the 353 patients, only 150 (42,5%) were 
addressed to the Laboratory facilities, where the clinical diagnosis was always confirmed. 
Based on this results, we assumed that all the confirmed clinical diagnoses were correct. 
This way we calculated the disease incidence, (Kaposi Sarcoma cases number/whole 
DREAM cohort x 1000), for the considered period, about 4 years. Our results show that 
the Sarcoma incidence °/°° in Mozambique  is 25,2. The only information we have found 
about Sarcoma incidence in the region before the AIDS pandemic in the area is about 
males  0-64 years old, being the rate between 1,5-3,5 % (In the North of  Mozambique the 
incidence was under 3,5 % and in the South of the country under 1,5%).(128)  
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The first evidence is that the incidence increases in the HIV+ cohort in all the Country  
especially in the Central area of the Country. The total incidence is tenfold the value 
registered in the past, before the AIDS era. If we consider Tab 9 we can observe the 
incidence related to each Health Centre. The highest values are registered in Quelimane 
(Central area) and Chokwe. In effect, we must remember that these Health Centres are 
inside Provincial Hospitals, and probably  received patients coming from a wider area than 
the other ones. Mahotas has a lower incidence, but almost all the patients are children. 
Nevertheless, the only 2 cases observed are adults. Matola has the lowest incidence, but 
this is a Centre in a “Unidade de Saude Materno Infantil”, (Mother-Child Health Division), 
so patients here are exclusively healthy women coming for the prenatal care, to whom also 
HIV testing is offered. Antiretroviral treatment is provided only for Mother to Child 
Prevention to the seropositive ones. 
Kaposi Sarcoma doesn’t increase in male group, like in Kaposi Sarcoma classic form, but 
it seems that females are more represented in the Kaposi group than in the HIV+ cohort 
(DREAM  64,7% C.I. 1,004, KS cohort 79,1% C.I. 3,23).  
Patients with Kaposi Sarcoma are older than others. In fact,  the disease is characteristic 
of old infection and this is the reason why the Kaposi Sarcoma cohort is more aged. tab 10 
Patients with KS  are identified at first contact, during the clinical visit. They represent an 
elevated risk  group. CD4 are very low (baseline median 188 cells/ul3) and viral load 
moderately high (baseline 55.000 copies/ml - 4,7404 log10). 
All these patients started therapy immediately with the first-line regimen. 
When possible, patients were transferred to the Maputo Central Hospital for specific 
treatment based on a combination of three different drugs, doxorubicin, bleomycin and 
vincristine (ABV). 
Observing haematic  parameters (CD4 and viral load) in the KS group, during the 
antiretroviral treatment,  we noted a CD4 increase up to 263 cells/ul3 median value, 40% 
more than the baseline value, and viral load is undetectable (<50 copies/ml) after 6 
months. The same haematic parameters in the DREAM cohort (receiving HAART) are: 
CD4 155 (+- 54) cells/ul3  baseline, 348 (+-72) after 6 months of HAART, increasing of 
124,5%, and viral load 15.600 baseline undetectable (<50 copies/ml) after 6 months 
decreasing of 97,9%. Tab 11 
We can observe a very good response in the whole DREAM cohort on treatment, due to 
the efficacy of therapeutic line and the good patients' adherence. Both groups show an 
evident virological decrease. The immunological response is good also in the KS group, 
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even if among these patients a part (12%) is treated with cytostatics and the 
immunological  improvement is lower than the whole cohort, due to  the chemotherapy 
immunosuppression. 
Analysing  the KS group, and comparing CD4 values (tab 12)  in patients receiving HAART 
and cytostatics (A), and  in patients receiving only HAART (B), we can observe that in the 
group A the baseline CD4 median value is 296 cells/ul3 and after 6 months 319 cells/um3; 
The group B has the baseline CD4 median value 188 cells/ul3, and after 6 months 262 
cells/ul3. It is evident that the immunological increase is difficult in group receiving 
cytostatics. 
The problem seems to endure the indispensable time to obtain the drug’s effects. If in the 
whole DREAM cohort, mortality is about the 7%, and patients need about 45 days' 
treatment , (the higher mortality is in this first period), in the KS sub cohort mortality is high 
(71 patients, the 13,5%) but concentrated in the first 80 days of treatment. Probably in this 
group of patients therapy needs more time to deploy its efficacy. 
 
Machava Centre: Patients with  Kaposi Sarcoma  
Then, we analysed in details the first Health Centre activity, the Machava Centre, closed to 
the capital, Maputo, in the South of the Country. The data are referred to 4 years' activities.  
First of all,  from our general data about HHV8 prevalence in the Country, we extrapolated  
the HHV8 prevalence in the local HIV+ cohort. In Machava Centre it was about 51,8% (on 
133 screened patients) vs 51,07% being the prevalence of the Country, a very similar 
value. The Sarcoma incidence is 27,1 (2246 enrolled patients) vs 25,2 of the Country, very 
close to the general one.  All Kaposi Sarcoma diagnoses were confirmed at the 
Pathological Anatomy Laboratory-Central Hospital of Maputo. 
Among 61 KS patients, 31 patients died (50,8%) and 3 were transferred to other health 
centres.  
 So, we have in follow up 27 patients, 39 median age, 15 males (56%) and 12 females 
(44%). Here we cannot find  gender difference. 
Studying the 27 cases, it is evidenced that the Sarcoma diagnosis was done at the first 
visit, when the CD4 count was less than 200 cells/ul3 in 70% of cases, with median value 
of 183 cellss/ul3. As usual, all of them were in the 4th WHO Clinical Stage and they started 
the antiretroviral treatment.  
About the diagnosis of Kaposi Sarcoma, we found 8 cutaneous, 14 lower or upper limbs 
localized, 3 mouth and tongue and 2 scattered Sarcomas.  
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At the end of the study, 4 patients had been on treatment for more then three years, 11 
patients for more then two years, 9 patients for more than one year, 2 for more than six 
months and only 1 patient had been on treatment for just two months.  
Only two patients have not immediately started the HAART treatment at the first visit, due 
to TB presence. 
Two patients moved to the second line for treatment failure. A Protease inhibitor  was 
introduced and the new treatment regimen was: 
 
ddI +ABC +IND 
 
Among the 27 patients, 15 (55,5%) started also a specific KS treatment, at the Maputo 
Central Hospital with doxorubicin, bleomycin and vincristine (ABV).14 of them with 
cytostatics and 1 patient started with radiotherapy and then was treated also with 
cytostatics.   
As regards to antiretroviral regimen, 6 patients were treated with Indinavir (IDV) and not 
NVP, 5 of them were also under cytostatic treatment. 
Among the 15 treated patients, one showed a complete remission, 7 were asymptomatic 
and 7 were in regression but still with some lesions. 
Among the 12 untreated, 1 patient was in complete remission, 9 were asymptomatic and  
2 still showed lesions, with one going into developing more lesions.  
In the  treated patients, the Sarcoma reverted in 8 patients after 12 months of both 
treatments (Chemotherapy and HAART). 
In the untreated patients, who didn’t start chemotherapy, the Sarcoma reverted in 10 
cases, in 18 – 30 months, only with antiretroviral drugs.  
About the 2 patients in second line, one was under chemotherapy too, while the other 
wasn't, and still there was an objective tumour regression within 1 year. 
Among the 10 untreated patients reaching the asymptomatic state, 83%, had initial 
diagnosis of sarcoma (4 cutaneous, 2 mouth and tongue, 3 lower or upper limbs localized 
and 1 scattered sarcoma).  
Among the 8 treated patients (53%) reaching the asymptomatic state, the initial diagnoses 
were 3 cutaneous, 4 limbs and 1 scattered sarcoma. (tab. 13). This result seems quite 
strange, but  we must considere that the group A patients (treated also with cytostatics) 
have become asymptomatyc more quickly than the B group, even if it is difficult to 
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measure the statistical significance. In fact it was difficult to determine the exact moment 
when the Sarcoma disappeared.    
About the 30 dead, we note that 26 patients (87%) have not started HAART (13 patients) 
or had been under treatment for less than 1 month (13 patients). This agreed with the 
evidence of the whole DREAM Cohort, where we noted that patients need at least 1 
month's therapy to survive (5) Only four patients had been under antiretroviral treatment 
for more than 1 month when they died. About chemotherapy, only 4 patients (13,3%)  
started the treatment, but not the HAART. Tab 14 shows the baseline immunological and 
virological state for the survivors and the dead. As for immunological state, the difference 
between the two groups is statistically significant, with p<0,0005. This is the real reason for 
death. Unfortunately, as they were admitted, they were in worse conditions and 
antiretroviral therapy had no enough time to operate.  
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CONCLUSIONS 
 
A major challenge for the Sub Saharan African health care providers is the implementation 
of an effective HIV therapeutic programme, supported by a minimum of laboratory 
monitoring that may guide patient management at locally affordable costs. Implementing 
laboratory facilities and cost-effective methods is possible in resource-limited settings. 
Conventional flow cytometry, adapted to meet locally affordable requirements still stands 
as the cheapest, yet most reliable and accurate technique to measure CD4 + T cells on a 
routine basis. Panleucogating uses only two antibodies (anti-CD45 and anti-CD4) and 
gives a clear-cut identification of CD4 + cells over the whole WBC and over lymphocytes 
as well. In particular CD4 + lymphocytes (CD45 high SS low CD4 high ) are easily 
distinguished here from monocytes, whereas this does not occur when the gating strategy 
is based solely on physical parameters. In the PLG protocol it is also possible to add CD8-
PCy5 in the same tube when the CD4/CD8 is requested. This represents a convenient and 
interesting alternative to the routine triple -color approach. 
 
Viral load quantification, beside other tests as ELISA or biochemistry are now  available 
also in Mozambique. Setting up the laboratory allowed us regular monitoring of 
antiretroviral therapy and potential toxicities. And in addition, it assisted us in monitoring 
HHV8 distribution, and studying immunological and virological characteristics of HIV+ 
patients with Kaposi Sarcoma.  
 
This study confirms the free circulation of the HHV8 virus in the Mozambican population, 
with a prevalence rate (51,1%) similar to the one measured by other authors and with 
other analytical methods in bordering Countries, like Malawi and Zambia. Furthermore, it 
has emerged that in Mozambique, in the studied population, there is no association 
between seroprevalence for HIV and HHV8. The HHV8 prevalence, indeed, is similar 
between HIV positive and negative group. The higher incidence of Kaposi Sarcoma in the  
HIV-positive patients is probably related to other factors and different cofactors, such as 
human immunodeficiency virus (HIV) proteins, host-derived cytokines, chemokines, and 
growth factors, that seem to be required for the development of KS. 
 
Immunosuppression as HIV-positive patients pass to the AIDS stage is not enough to 
explain the Kaposi Sarcoma clinical evidence.  It should be noted that an 
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immunocompromised state is due to many other causes, not least, in the area under 
study, malnutrition, also in HIV -negative subjects. Nevertheless, using Haemoglobin levels 
and Body Mass Index as indicators, we have not found, in our population, any correlation 
with HHV8 positivity. 
 
The expression of viral proteins capable of inactivating the p53 tumor suppressor protein 
has been implicated in KSHV oncogenesis, (38) and some authors like Whitby D and 
others have proposed environmental cofactors present in KS endemic regions to explain 
frequent reactivation of KSHV in infected subjects. (118)  
As regards the HIV -positive cohort, the valuation of immunological and virological 
parameters in relation to positivity for HHV8 reveals a significant association as to CD8 
values, suggesting the existence of one or more factors correlated to the two parameters. 
The function of cytotoxic T lymphocytes (CD8+T cells) in immunity to HHV8 in healthy 
individuals and in patients infected with HIV, and the role played by dendritic cells in the 
development of this immune response is under study. This research includes the 
characterization of immunodominant regions involved in the control of HHV8 infection by 
CD8+ T cells and their role in the progression to Kaposi’s sarcoma in immunodeficient 
individuals. (117) 
 
According to literature, the Kaposi Sarcoma related with AIDS is different from the Classic 
African Sarcoma. In Mozambique the incidence is higher, up to tenfold the incidence 
registered before the AIDS diffusion, but not related with the HHV8 prevalence. There isn’t 
an increase in males, as in Classic form, but it seems that females are more represented 
in the group of patients with sarcoma. The tumour is responding to the antiretroviral 
treatment. The regression is evident even if patients are not treated with chemotherapy. 
Antiretroviral therapy increases the immunological response also in Kaposi Sarcoma 
patients, and also in patient group treated with cytostatics. The mortality is higher in the 
Kaposi Sarcoma group than in the whole cohort, but concentrated in the first 80 days of 
antiretroviral treatment. In addition, the group of dead patients showed worse 
immunological conditions. The presence of the tumour indicates a worse general condition 
in the patients, and an old HIV infection.   Probably in this group of patients therapy needs 
more time to deploy its efficacy.  
The evidence is that it is more important to treat AIDS, even if it is not possible to treat the 
correlate tumours like Kaposi Sarcoma.  
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Studying 27 patients in follow up in a DREAM Health Centre in Machava, since 2002 until 
the end of 2006, we noted that chemotherapy is not absolutely necessary to revert the 
most common kind of Kaposi Sarcoma excluding the pulmonary form. speeds up the 
regression and, even if it is always advisable, the most important thing is to start up the 
antiretroviral treatment, when chemotherapy is unavailable.  About the use of a Protease 
Inhibitor like Indinavir, the antiretroviral drug often indicated as the best treatment in case 
of Kaposi Sarcoma in HIV positive patients, it was not possible to determine the real 
efficacy due to the small number of patients treated with the drug. More studies will be 
necessary in the future to monitor the cost-effective use of Indinavir versus a fixed dose 
regimen to treat patients with Kaposi Sarcoma.  
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